Hear me out. Chris Sandburg articles usually aren’t
Hear me out. Chris Sandburg articles usually aren’t always accurate. I’ve been reading them for the past few years like many others, and although I like them I’m with you on this Chazz. Fuzzy to say the least… I do not think he knows more than most investors do.
I’m not sure where 10 keeps coming from, maybe he has a ton of shares like some and 10 will easily make him a multi millionaire and he just wants to play it safe and cash out. Don’t blame that mindset for many.
The company has had a bumpy road and a lot of mistakes were made along the way which makes 10 sound like a dream to some at this point. A lot was self inflicted but other mistakes were legitimately road blocks from the FDA and possibly BP. If you think it was all self inflicted or not it doesn’t matter the truth is things went slower than anticipated and covid fell flat.
However, it wasn’t too long ago when we were trading at 10 and people where talking about only selling some at 50 and riding the rest for triple digits. Yes triple digits. That’s actually not that unrealistic if we make it and see several approvals over the next 5-10 years.
So when I hear 10 dollars it makes me think of a few things. First people have their individual financial reasons to sell and they change often with time. I won’t get into that but pretty straight forward.
The second thing is, I believe it’s possible that whoever is interested in buying us, if that’s the case, would greatly benefit convincing share holders to sell at 10.
Right ? Because that would be the equivalent of buying something that was 99 precent on sale. So yes I’d be campaigning for 10 all day.
I know nobody asked but since we are on the subject…. I don’t have a single share for sale right now for 10 dollars. Now that doesn’t mean I won’t sell a single share on the way up at 10 this time. If anything it would only be a few thousand shares to say I didn’t miss out like last time and also finally pocket some cash. It would also be the financially smart thing for me to do. That’s why they call it individual financials . Everyone’s different.
So yes 10 imo is a joke. This is also why I do not see a buyout coming. We are too expensive already. Who’s going to pay say 30 billion for a stock that’s trading with a 800 million dollar market cap ? I mean it’s possible but I don’t see it ? Prove me wrong and offer us 50 then we can talk but I don’t see it.
Way too many possible indications. This isn’t a one trick show. The share price could actually be well over 100 dollars in 10 years yet people want to sell at 10?! What ?!
This is why I believe a partner would be best or maybe some other share for share swap so we can watch Leronlimab grow. We have very loyal share holders that wanna see this to the end. So BP if you are listening you might want to think twice about offering 10 dollars . It could cost you more than you think…
25
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...
Continue Reading
Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...
Continue Reading
When Maesa pulls back the curtain, they don't just crack it open—they fling it aside with flair. That's precisely what they're doing with their latest venture, Anecdotes by Artists, a fragrance brand that's taking its first bow exclusively at Sephora. It's not your average perfume launch; it's about the stories behind the scents and the artists who craft them. Unveiling...
Continue Reading
AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...
Continue Reading
Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...
Continue Reading
Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...
Continue Reading
AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...
Continue Reading
America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...
Continue Reading
In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...
Continue Reading
Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...
Continue Reading
Top 5 Most Recently Viewed Articles
Overview of Novo Nordisk's Recent Stock Surge Novo Nordisk A/S (NYSE: NVO) has recently experienced a significant increase in its stock price, rising over 7% in premarket trading following its groundbreaking regulatory approval from the U.S. Food and Drug Administration (FDA). This approval marks an exciting development for the company, as the FDA has approved their oral...
Continue Reading
Discover BitStarz: A Leader in Instant Payout Casinos In the world of online casinos, speed and efficiency are paramount for players eager to enjoy their winnings. BitStarz Casino stands out as a trusted platform dedicated to delivering instant withdrawals and fast payouts, making it a must-visit for online gaming enthusiasts in 2025. Why BitStarz is the Go-To Casino for...
Continue Reading
Introducing Gridora: A Groundbreaking Infrastructure Venture The establishment of Gridora marks an exciting shift in how strategic infrastructure projects will be developed. Created as a joint venture involving major entities ADQ, IHC, and Modon Holding, this new platform is set to enhance the collaborative efforts between the public and private sectors. With a shared...
Continue Reading
WisdomTree Monthly Performance Review WisdomTree, Inc. (NYSE: WT), a notable player in financial innovation, has recently released an in-depth report detailing its monthly performance metrics. This report highlights impressive growth and offers valuable insights into the company’s assets under management (AUM) and fund flow performance. As a vital participant in the...
Continue Reading
Recent Legal Developments in Phoenix In a notable case linked to a police shooting, Attorney Dave Erlichman of Comeback Law P.C. represents Essa Williams, who faces criminal charges after shooting Phoenix Police Officer Tyler Moldovan. Williams's defense hinges on self-defense claims, but recent statements by former President Trump have introduced significant controversy...
Continue Reading